Contact this trialFirst, we need to learn more about you.
Topoisomerase I inhibitors
ELU001 for Ovarian and Endometrial Cancers
Recruiting1 awardPhase 1 & 2
Peoria, Illinois
This trial is focused on subjects with advanced, recurrent or refractory FRα overexpressing tumors. ELU001 is a new chemical entity consisting of payloads and targeting moieties covalently bound by linkers to the C'Dot particle carrier. This is the first trial of its kind and a novel molecular entity.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.